-
Net Sales of $23.1 Million, Up 27.3% from Q3 FY 2014
-
Gross Margin of 43.9%, Up 340 Basis Points from Q3 FY 2014
-
Operating Margin of 11.1%, Up 460 Basis Points from Q3 FY 2014
-
Diluted EPS of $0.20, Up from $0.14 in Q3 FY 2014
-
Company Completes Integration of Miltope Acquisition
WEST WARWICK, R.I.--(BUSINESS WIRE)--Nov. 26, 2014--
Astro-Med, Inc. (NASDAQ: ALOT), a leading manufacturer of specialty
high-tech printing systems and data acquisition products, today reported
net sales of $23.1 million for the three months ended November 1, 2014,
an increase of 27.3% from the same period a year earlier. Net income for
the fiscal third quarter of 2015 was $1.6 million, or $0.20 per diluted
share, compared with net income of $1.1 million, or $0.14 per diluted
share, for the same period a year earlier.
“By concentrating on three key areas – product development,
manufacturing efficiency and geographic expansion – we are achieving
increasing levels of operational and financial success,” said Astro-Med
President and Chief Executive Officer, Gregory A. Woods. “Our
third-quarter performance reflected these efforts. Solid demand across
all product lines generated record third-quarter net sales, as our
QuickLabel Systems (QLS) and Test & Measurement (T&M) segments increased
approximately 22% and 39%, respectively. Both our domestic and
international sales channels contributed nicely to the Company’s
top-line growth.”
“Higher revenue, combined with the success of our ongoing lean
manufacturing initiatives, contributed to a 340 basis-point increase in
our gross margin, which grew to 43.9% in the quarter,” Woods said. “Even
as we stepped up investments in marketing and R&D, our operating profit
increased to $2.6 million, or 11.1% of net sales, from $1.2 million, or
6.5% of net sales, in the third quarter of fiscal 2014. This
demonstrates continued improvement in our operating leverage.”
For the nine months ended November 1, 2014, Astro-Med reported net sales
of $66.3 million, an increase of 30.3% over the prior year sales of
$50.9 million for the same period. The Company reported net income of
$4.1 million, or $0.52 per diluted share, for the first nine months of
fiscal 2015 compared with $1.4 million, or $0.18 per diluted share, for
the same period of fiscal 2014. The fiscal 2014 results included a
reserve established to address a non-compliant component in a limited
number of ToughWriter Printers. The after-tax cost of this reserve was
equal to $0.06 per diluted share. Excluding the impact of this reserve,
the Company’s net income on a non-GAAP basis for the nine months ended
November 2, 2013 was $1.8 million, or $0.24 per diluted share.
At November 1, 2014, Astro-Med had cash and cash equivalents totaling
$30.9 million, compared with $27.1 million at January 31, 2014.
Recent Highlights:
-
New QLS Products – Astro-Med launched the industry’s first full
line of color digital label printers using pigment-based ink for
ultra-durable labels. Three printer models – the Kiaro! D, Kiaro! 200D
and Kiaro! 50D – were unveiled at PACK EXPO International 2014, the
largest packaging and processing trade show in North America. The
printers are designed for non-laminated industrial labels that will be
exposed to sunlight, chemicals, moisture, dirt or other harsh
conditions that would otherwise test their legibility and color
fastness. The Company also introduced the Kiaro! 50, a narrow-format
digital color label printer specifically designed for labels sized 1”
to 2.16” wide.
-
Aircraft Printer – Hong Kong-based Cathay Pacific Airways
selected Astro-Med’s NP4840 network printer for its eEnabled Aircraft
program.
-
Miltope Integration Complete – Astro-Med completed the
integration of the Miltope acquisition in the third quarter as
planned. Manufacturing for Miltope’s aerospace printer line has been
fully transitioned from Alabama to Astro-Med’s manufacturing facility
in West Warwick, RI.
-
Expansion of Direct Sales in Asia – Tapping into what is
considered a significant area for growth, Astro-Med achieved its goal
of expanding into Southeast Asia with the opening of a Malaysia office
in the third quarter. Further expansion in the Asia Pacific region is
planned for the fourth quarter of fiscal 2015.
Board of Directors Declares Regular Quarterly Dividend
On November 24, 2014, the Directors of Astro-Med, Inc. declared a
regular quarterly cash dividend of $0.07 per share. The dividend, which
represents a cash dividend of $0.28 per share on an annualized basis, is
payable January 2, 2015 to shareholders of record on December 19, 2014.
Business Outlook
“We will continue to drive AMI’s strategy of global growth, expanded
distribution, and productivity improvement in the final quarter of
fiscal 2015 and beyond. However, given the uncertainty evident in
certain European markets, coupled with the upcoming final stage of our
Oracle ERP conversion, we are facing some additional headwinds in our
fourth quarter,” Woods said. “Notwithstanding these issues, both of our
segments are increasing their competitive positions in the market. In
the QLS segment, our new pigment ink-based and narrow-format
technologies continue to raise the bar for quality, performance and cost
efficiency. Within the T&M segment, demand for our ruggedized aerospace
printers is strong in both the airline-direct and OEM markets, and our
established data acquisition technology continues on a growth path.”
Q3 Fiscal 2015 Conference Call
The third-quarter fiscal 2015 financial results conference call will be
held today, Wednesday, November 26, 2014 at 9:00 a.m. EST. It will be
broadcast in real time on the Internet through the “Investors” section
of the Company’s website at www.Astro-MedInc.com.
You also may participate in the conference call by dialing 888-466-4440
(U.S. and Canada) or 719-457-2704 (International) with passcode 393116.
Following the live broadcast, an audio webcast of the call will be
available at www.Astro-MedInc.com.
A telephone replay of the conference call will be available for seven
days by dialing 888-203-1112 (U.S. and Canada) or 719-457-0820
(International) with passcode 8012121.
About Astro-Med, Inc.
Astro-Med, Inc. is a leading manufacturer of specialty high tech
printing systems and data acquisition systems. Products include color
label printers and consumables sold under the QuickLabel Systems brand
as well as ruggedized printers for aerospace, defense applications, and
data acquisition products sold under the Astro-Med brand. Astro-Med,
Inc. is a member of the Russell Microcap® Index. Additional information
is available by visiting www.Astro-MedInc.com.
Forward-Looking Statements
Information included in this news release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not statements of
historical fact, but rather reflect our current expectations concerning
future events and results. These statements may include the use the
words “believes,” “expects,” “intends,” “plans,” “anticipates,”
“likely,” “continues,” “may,” “will,” and similar expressions to
identify forward-looking statements. Such forward-looking statements,
including those concerning growth through acquisitions, involve risks,
uncertainties and other factors, some of which are beyond our control,
which may cause our actual results, performance or achievements to be
materially different from those expressed or implied by such
forward-looking statements. These risks, uncertainties, and factors
include, but are not limited to, those factors set forth in the
Company’s Annual Report on Form 10-K for the fiscal year ended January
31, 2014 and subsequent filings Astro-Med makes with the Securities and
Exchange Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. The reader is cautioned not
to unduly rely on such forward-looking statements when evaluating the
information presented in this news release.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally
accepted accounting principles (GAAP), this press release also contains
the Non-GAAP financial measures, Non-GAAP net income and diluted EPS.
The Company believes that the inclusion of these non-GAAP financial
measures in this press release helps investors to gain a meaningful
understanding of changes in the Company's core operating results, and
also can help investors who wish to make comparisons between Astro-Med
and other companies on both a GAAP and a non-GAAP basis. Astro-Med’s
management uses these non-GAAP measures, in addition to GAAP financial
measures, as the basis for measuring its core operating performance and
comparing such performance to that of prior periods and to the
performance of its competitors. These measures are also used by the
Company’s management to assist with their financial and operating
decision making.
|
|
ASTRO-MED, INC. Consolidated Statements of
Operations In Thousands Except for Per Share Data (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three-Months Ended
|
Nine-Months Ended
|
|
|
|
|
|
November 1, 2014
|
|
|
|
|
November 2, 2013
|
|
|
|
|
November 1, 2014
|
|
|
|
|
November 2, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales
|
|
|
|
|
$
|
23,137
|
|
|
|
|
|
$
|
18,179
|
|
|
|
|
|
$
|
66,277
|
|
|
|
|
|
$
|
50,858
|
|
Cost of Sales
|
|
|
|
|
|
12,985
|
|
|
|
|
|
|
10,816
|
|
|
|
|
|
|
37,901
|
|
|
|
|
|
|
30,796
|
|
Product Replacement Related Costs
|
|
|
|
|
|
-
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit
|
|
|
|
|
|
10,152
|
|
|
|
|
|
|
7,363
|
|
|
|
|
|
|
28,376
|
|
|
|
|
|
|
19,390
|
|
|
|
|
|
|
|
43.9%
|
|
|
|
|
|
|
40.5%
|
|
|
|
|
|
|
42.8%
|
|
|
|
|
|
|
38.1%
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and Marketing
|
|
|
|
|
|
4,606
|
|
|
|
|
|
|
3,727
|
|
|
|
|
|
|
13,483
|
|
|
|
|
|
|
10,680
|
|
Research and Development
|
|
|
|
|
|
1,564
|
|
|
|
|
|
|
1,230
|
|
|
|
|
|
|
4,414
|
|
|
|
|
|
|
3,617
|
|
General and Administration
|
|
|
|
|
|
1,407
|
|
|
|
|
|
|
1,223
|
|
|
|
|
|
|
4,041
|
|
|
|
|
|
|
3,745
|
|
|
|
|
|
|
|
7,577
|
|
|
|
|
|
|
6,180
|
|
|
|
|
|
|
21,938
|
|
|
|
|
|
|
18,042
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income
|
|
|
|
|
|
2,575
|
|
|
|
|
|
|
1,183
|
|
|
|
|
|
|
6,438
|
|
|
|
|
|
|
1,348
|
|
|
|
|
|
|
|
11.1%
|
|
|
|
|
|
|
6.5%
|
|
|
|
|
|
|
9.7%
|
|
|
|
|
|
|
2.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Expense, Net
|
|
|
|
|
|
(46)
|
|
|
|
|
|
|
(2)
|
|
|
|
|
|
|
(85)
|
|
|
|
|
|
|
(64) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Continuing Operations Before Taxes
|
|
|
|
|
|
2,529
|
|
|
|
|
|
|
1,181
|
|
|
|
|
|
|
6,353
|
|
|
|
|
|
|
1,284
|
|
Income Tax Provision for Continuing Operations
|
|
|
|
|
|
974
|
|
|
|
|
|
|
436
|
|
|
|
|
|
|
2,235
|
|
|
|
|
|
|
446
|
|
Income from Continuing Operations
|
|
|
|
|
|
1,555
|
|
|
|
|
|
|
745
|
|
|
|
|
|
|
4,118
|
|
|
|
|
|
|
838
|
|
Income from Discontinued Operations, Net of Taxes
|
|
|
|
|
|
-
|
|
|
|
|
|
|
363
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
|
|
|
|
|
$
|
1,555
|
|
|
|
|
|
$
|
1,108
|
|
|
|
|
|
$
|
4,118
|
|
|
|
|
|
$
|
1,355
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share – Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income per share from Continuing Operations
|
|
|
|
|
$
|
0.20
|
|
|
|
|
|
$
|
0.10
|
|
|
|
|
|
$
|
0.54
|
|
|
|
|
|
$
|
0.11
|
|
Net Income per share from Discontinued Operations
|
|
|
|
|
|
-
|
|
|
|
|
|
|
0.05
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
0.07
|
|
Net Income per share - Basic
|
|
|
|
|
$
|
0.20
|
|
|
|
|
|
$
|
0.15
|
|
|
|
|
|
$
|
0.54
|
|
|
|
|
|
$
|
0.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share – Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income per share from Continuing Operations
|
|
|
|
|
$
|
0.20
|
|
|
|
|
|
$
|
0.10
|
|
|
|
|
|
$
|
0.52
|
|
|
|
|
|
$
|
0.11
|
|
Net Income from Discontinued Operations
|
|
|
|
|
|
-
|
|
|
|
|
|
|
0.04
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
0.07
|
|
Net Income per share - Diluted
|
|
|
|
|
$
|
0.20
|
|
|
|
|
|
$
|
0.14
|
|
|
|
|
|
$
|
0.52
|
|
|
|
|
|
$
|
0.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Avg Number of Common Shares - Basic
|
|
|
|
|
|
7,730
|
|
|
|
|
|
|
7,490
|
|
|
|
|
|
|
7,678
|
|
|
|
|
|
|
7,449
|
|
Weighted Avg Number of Common Shares - Diluted
|
|
|
|
|
|
7,926
|
|
|
|
|
|
|
7,716
|
|
|
|
|
|
|
7,897
|
|
|
|
|
|
|
7,650
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends Declared Per Common Share
|
|
|
|
|
$
|
0.07
|
|
|
|
|
|
$
|
0.07
|
|
|
|
|
|
$
|
0.21
|
|
|
|
|
|
$
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selected Balance Sheet Data
|
in Thousands
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
|
As of
|
|
|
|
|
|
November 1, 2014
|
|
|
|
|
January 31, 2014
|
Cash & Marketable Securities
|
|
|
|
|
$30,903
|
|
|
|
|
$27,107
|
Current Assets
|
|
|
|
|
$69,010
|
|
|
|
|
$65,034
|
Total Assets
|
|
|
|
|
$81,753
|
|
|
|
|
$77,964
|
Current Liabilities
|
|
|
|
|
$10,569
|
|
|
|
|
$9,892
|
Shareholders’ Equity
|
|
|
|
|
$70,095
|
|
|
|
|
$66,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Adjustments in Thousands (Unaudited)
|
|
|
|
|
|
|
Three-Months Ended
|
|
|
|
|
Nine-Months Ended
|
|
|
|
|
|
November 1, 2014
|
|
|
|
|
November 2, 2013
|
|
|
|
|
November 1, 2014
|
|
|
|
|
November 2, 2013
|
GAAP based results as reported:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
|
|
|
|
|
$
|
1,555
|
|
|
|
|
$
|
1,108
|
|
|
|
|
$
|
4,118
|
|
|
|
|
$
|
1,355
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product Replacement Costs
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
423
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Net Income
|
|
|
|
|
$
|
1,555
|
|
|
|
|
$
|
1,108
|
|
|
|
|
$
|
4,118
|
|
|
|
|
$
|
1,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP based results as reported:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EPS -diluted
|
|
|
|
|
$
|
0.20
|
|
|
|
|
$
|
0.14
|
|
|
|
|
$
|
0.52
|
|
|
|
|
$
|
0.18
|
Non-GAAP adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product Replacement Costs
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
-
|
|
|
|
|
|
0.06
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP EPS - diluted
|
|
|
|
|
$
|
0.20
|
|
|
|
|
$
|
0.14
|
|
|
|
|
$
|
0.52
|
|
|
|
|
$
|
0.24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Source: Astro-Med, Inc.
for Astro-Med, Inc.
Joseph P. O’Connell, (800) 343-4039
Senior
Vice President, Chief Financial Officer